|
시장보고서
상품코드
2131466
만성 유연증 시장 규모, 점유율, 성장 분석 : 치료 유형, 적응증별, 투여 경로별, 최종사용자별, 유통 채널별, 환자층별, 지역별 - 산업 예측(2026-2033년)Chronic Sialorrhea Market Size, Share, and Growth Analysis, By Treatment Type, By Indication, By Route of Administration, By End User, By Distribution Channel, By Patient Group, By Region - Industry Forecast 2026-2033 |
||||||
세계의 만성 유연증 시장 규모는 2024년에 4억 8,630만 달러로 평가되며, 2025년 5억 7,432만 달러에서 2033년까지 21억 7,347만 달러로 확대될 전망이며, 예측 기간(2026-2033년) 동안 CAGR 18.1%로 성장할 것으로 전망됩니다.
세계 만성 유연증 시장은 파킨슨병이나 뇌성마비 등 신경계 질환을 앓고 있는 환자의 과도한 타액 분비를 관리하는 혁신적인 치료법을 중심으로 전개되고 있습니다. 타액이 사회적 교류, 피부 건강, 호흡기 상태에 미치는 영향이 효과적인 치료법에 대한 수요를 뒷받침하고 있습니다. 최근 동향으로는 기존의 항콜린제에서 보다 표적화된 주사제나 조절제로의 전환이 나타나고 있으며, 보험 적용 범위 확대를 통해 환자의 접근성이 향상되고 있습니다. 또한, 원격의료 서비스의 보급으로 원격 평가 및 투여량 조정이 용이해져 내원 횟수와 비용을 절감하는 동시에, 간병인 및 고령 환자의 치료 순응도를 높이고 있습니다. AI를 활용한 신약 개발을 도입함으로써 표적 규명 및 분자 설계가 최적화되고, 부작용이 적은 새로운 치료법이 개발됨에 따라 투자가 활성화되어 지속가능한 시장 성장이 촉진되고 있습니다.
세계 만성 유연증 시장의 성장요인
세계 만성 유연증 시장은 의료진이 환자에게 해당 질환 및 이것이 삶의 질(QOL)에 미치는 중대한 영향에 대해 인식 제고를 위한 기회를 늘리고 있는 데 힘입어 성장하고 있습니다. 이러한 인식 제고 노력은 타액 과다 분비증에 수반되는 사회적 편견을 완화하고, 더 많은 환자가 조기에 의료 상담을 받도록 유도하고 있습니다. 그 결과, 효과적인 치료법에 대한 수요가 증가하고 있으며, 제조사들은 제품 라인 확충과 투여 방식의 혁신을 요구받고 있습니다. 이러한 추세는 지식이 풍부하고 주체적인 환자층에 의해 더욱 뒷받침되고 있으며, 다양한 지역에서의 시장 성장, 전문 클리닉과의 연계 강화, 환자 지원 단체 및 지역사회를 대상으로 한 인식 제고 활동의 활성화를 촉진하고 있습니다.
세계 만성 유연증 시장의 억제요인
세계 만성 유연증 시장은 많은 의료 제도의 보험 급여 정책 제한으로 인해 중대한 과제에 직면해 있습니다. 이러한 재정적 제약은 특히 새로운 주사제나 특수 의료기기에 영향을 미치고 있어, 환자들이 최적의 치료를 받기 어려워지고 있습니다. 그 결과, 임상의들은 보험 적용이 용이하지만 효과가 떨어지는 대체 요법에 의존할 수밖에 없는 경우가 많아, 혁신적인 치료법의 전반적인 보급을 저해하고 있습니다. 제조사들은 가격 전략의 정당성을 설명하거나 보험사와의 복잡한 협상을 진행하는 데 장애에 직면하고 있으며, 이는 이러한 치료법에 대한 더 광범위한 접근을 제한하고 있습니다. 이러한 상황은 시장 성장 잠재력을 저해할 뿐만 아니라, 신흥 시장에서 치료 선택지를 확대하기 위한 연구 이니셔티브에 대한 투자도 제한하고 있습니다.
세계 만성 유연증 시장의 동향
세계 만성 유연증 시장에서는 원격의료 서비스 통합을 향한 뚜렷한 추세가 나타나고 있으며, 이는 환자 관리와 접근 방식에 변화를 가져오고 있습니다. 원격의료 플랫폼이 만성 유연증를 평가하기 위한 전문 도구를 도입함에 따라 원격 진단 및 지속적인 모니터링이 가능해져, 치료에 있어 지리적 장벽을 효과적으로 해소하고 있습니다. 이러한 혁신으로 치료 시작이 가속화되고, 온라인 후속 관리를 통해 치료의 연속성이 향상되고 있습니다. 보험사들은 원격 관리에 따른 비용상의 이점을 점점 더 인식하고 있으며, 그 결과 도입률이 높아지고 있습니다. 이에 따라 의료기기 제조사들은 환자의 복약 순응도와 치료 성과를 추적하는 기능을 강화한 디지털 동반자 앱을 개발하고 있으며, 텔레헬스는 시장 내 중요한 촉진요인으로서의 입지를 공고히 하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 만성 유연증 시장 규모 : 치료 유형별
세계의 만성 유연증 시장 규모 : 적응증별
세계의 만성 유연증 시장 규모 : 투여 경로별
세계의 만성 유연증 시장 규모 : 최종사용자별
세계의 만성 유연증 시장 규모 : 유통 채널별
세계의 만성 유연증 시장 규모 : 환자층별
세계의 만성 유연증 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.10.01Global Chronic Sialorrhea Market size was valued at USD 486.3 Million in 2024 and is poised to grow from USD 574.32 Million in 2025 to USD 2173.47 Million by 2033, growing at a CAGR of 18.1% during the forecast period (2026-2033).
The global chronic sialorrhea market is centered on innovative therapies that manage excessive saliva production in individuals affected by neurological disorders, such as Parkinson's disease and cerebral palsy. The impact of drooling on social interactions, skin health, and respiratory conditions drives demand for effective treatments. Recent trends indicate a shift from traditional anticholinergic drugs to more targeted injectable agents and modulators, enhancing patient access through improved insurance coverage. Additionally, the rise of telehealth services facilitates remote assessments and dosage adjustments, reducing clinic visits and costs while promoting adherence among caregivers and elderly patients. Incorporating AI-based drug discovery optimizes target identification and molecular design, leading to novel therapies that offer fewer side effects, stimulating investment and encouraging sustainable market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Sialorrhea market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chronic Sialorrhea Market Segments Analysis
Global chronic sialorrhea market is segmented by treatment type, indication, route of administration, end user, distribution channel, patient group and region. Based on treatment type, the market is segmented into Drug Therapy, Botulinum Toxin Therapy, Surgical Treatment and Others. Based on indication, the market is segmented into Parkinson's Disease, Cerebral Palsy, ALS and Others. Based on route of administration, the market is segmented into Oral, Injectable and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on patient group, the market is segmented into Pediatric and Adult. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chronic Sialorrhea Market
The global chronic sialorrhea market is being driven by healthcare professionals who are increasingly educating patients about the condition and its significant effects on quality of life. This focus on awareness serves to diminish stigma associated with sialorrhea, leading to more patients seeking medical advice sooner. As a result, there is a rising demand for effective treatment options, which compels manufacturers to broaden their product lines and innovate in terms of delivery methods. This trend is further fueled by a more informed and proactive patient population, fostering market growth across various regions, enhanced connections with specialist clinics, and greater activity from patient support groups and community outreach efforts.
Restraints in the Global Chronic Sialorrhea Market
The Global Chronic Sialorrhea market faces significant challenges due to limited reimbursement policies offered by many healthcare systems. This financial constraint particularly affects newer injectable therapies and specialized devices, making it difficult for patients to access optimal treatment. As a result, clinicians often resort to more readily covered, yet less effective alternatives, hindering the overall adoption of innovative solutions. Manufacturers encounter obstacles in justifying their pricing strategies and navigating complex negotiations with payers, which restricts broader accessibility to these therapies. This situation not only dampens market growth potential but also limits investments in research initiatives aimed at advancing treatment options in emerging markets.
Market Trends of the Global Chronic Sialorrhea Market
The Global Chronic Sialorrhea market is witnessing a significant trend towards the integration of telehealth services, which is reshaping patient care and accessibility. As telehealth platforms adopt specialized tools for assessing chronic sialorrhea, they facilitate remote diagnosis and ongoing monitoring, effectively breaking down geographic barriers to treatment. This innovation accelerates the initiation of care and enhances continuity through virtual follow-ups. Insurers are increasingly recognizing the cost benefits associated with remote management, leading to greater adoption rates. Consequently, device manufacturers are responding by developing digital companion applications that enhance patient adherence and outcome tracking, solidifying telehealth's role as a critical growth driver in the market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Chronic Sialorrhea Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Drug Therapy
- Botulinum Toxin Therapy
- Surgical Treatment
- Others
Global Chronic Sialorrhea Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Parkinson's Disease
- Cerebral Palsy
- ALS
- Others
Global Chronic Sialorrhea Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
- Others
Global Chronic Sialorrhea Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Others
Global Chronic Sialorrhea Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Chronic Sialorrhea Market Size by Patient Group & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
Global Chronic Sialorrhea Market Size & CAGR (2026-2033)
- North America (Treatment Type, Indication, Route of Administration, End User, Distribution Channel, Patient Group)
- US
- Canada
- Europe (Treatment Type, Indication, Route of Administration, End User, Distribution Channel, Patient Group)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Indication, Route of Administration, End User, Distribution Channel, Patient Group)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Indication, Route of Administration, End User, Distribution Channel, Patient Group)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Indication, Route of Administration, End User, Distribution Channel, Patient Group)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merz Pharma GmbH & Co. KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Revance Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Supernus Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neurocrine Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lundbeck A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Endo International plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
